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T
his is the ﬁrst of four articles sum-
marizing presentations at the Sev-
enth World Congress on the Insulin
Resistance Syndrome, held in San Fran-
cisco,California,on5–7November2009,
pertaining to cellular mechanisms of in-
sulin resistance.
Circadian rhythms and insulin
resistance
Peter Grant (Leeds, U.K.) introduced the
topic of circadian rhythms and their rela-
tionship to insulin resistance. The thrifty
genotype hypothesis (1) suggests a sur-
vival advantage of insulin resistance, pre-
sumably during periods of famine.
Insulin resistance should then be consid-
ered a physiologic process, with duration
the critical issue, so that prolonged insu-
lin resistance leads to disease—rather
than what might be considered beneﬁcial
insulin resistance after increased nutrient
ingestion in preparation for famine. Ani-
mals that prepare themselves for hyper-
nation have adipocyte hypertrophy,
hyperphagia, inﬂammatory changes, hy-
perinsulinemai, hyperglycemia, and re-
duced energy expenditure—all short- to
medium-term processes. Seasonal ani-
mals have marked insulin resistance just
priortohibernation(2),withseasonalcy-
cling related to the fat phenotype; a sec-
ondary period of fat accumulation occurs
during springtime. There is an endoge-
nousclockthatsetsuposcillatingsystems
in virtually every tissue, synchronized by
a central clock regulatory mechanism.
“You disrupt the clock at your own peril,”
Grant noted, with sleep duration a risk
factor for development of diabetes. Car-
diovascular physiology is under circadian
variation, affecting blood pressure, endo-
thelial function, vascular tone, lipid me-
tabolism, platelet and leukocyte function,
and thrombosis. Effects of shift working
in man include gastrointestinal, repro-
ductive, and metabolic disturbances; in-
sulin resistance; fasting and postprandial
hypertriglyceridema; and increased risk
of cardiovascular disease (CVD), “so this
is not a minor change.” One could hy-
pothesize that seasonal insulin resistance
beneﬁtsthehibernatinganimal,but“man
seems,” Grant said, “to have completely
lostcontactwith‘theanimal,’...[putting]
on weight year after year.”
Joseph Bass (Chicago, IL) reviewed
information about the molecular clock
and its linkage to metabolic control.
There are hypothalamic areas regulating
weight gain and weight loss. Genetics
studies of rodents with the ob mutation
and of ﬂies with mutation of clock have
contributedtounderstandingtheseareas,
with positional cloning furthering under-
standing of the clock genes in mammals
andimprovingourunderstandingbothof
circadian rhythms and of appetite regula-
tion. The cloning of clock and its dimeric
partner Bmal shows alternating patterns
of stimulation and suppression. A num-
ber of transcription factors such as
PPAR, PPAR, and oxysterol ligands
“areco-wiredwiththeclock,”linkingme-
tabolism to diurnal rhythms and leading
Bass to raise the interesting question of
whetherdrugsaffectingthesenuclearfac-
tors might alter circadian rhythms.
Obesity represents imbalance be-
tween energy intake and expenditure,
with clock mutants having increased in-
take accounting for weight gain in a fash-
ion parallel to human obesity, which also
may involve disruption in circadian
rhythms. The normal mouse eats mostly
in the dark period (since mice are noctur-
nal), but clock mutant mice are what Bass
termed “people-ized,” with increased
light and decreased dark food intake,
leading to increased adipose tissue and
liverfat,perhapsrelevanttothesefeatures
of the metabolic syndrome. clock is ex-
pressed in fat and liver and also in the
immune system, cardiovascular system,
kidney and gut, with disruption of circa-
dian rhythms then affecting metabolic
processes in all these tissues. Conversely,
Bass said, a high-fat diet disrupts the cir-
cadian rhythm, suggesting that the envi-
ronment alters the regulatory role of the
central clock mechanism and implying a
multiplicity of factors synchronizing the
organism’scircadianclock.Lifespancon-
trol is regulated by calorie availability,
with roles of sirtuins via nuclear stores of
the metabolic switch factor nicotinamide
adenine dinucleotide (NAD), as sirtuins
deacetylate histones and other factors in-
volved in gene transcription. Nuclear
NADdoesnotreﬂecttheredoxstateofthe
cell, as does mitochondrial NAD, but it-
selfvariesacrossthecircadiancyclerather
thansimplybeingaconstant“housekeep-
ing molecule” and, hence, can be thought
of as both detecting metabolic ﬂuxes and
couplingthesetochangingcircadiangene
regulatory cellular programs. Normal
metabolism requires entrainment of the
organismtoitsenvironment,correspond-
ing to periods of feeding and hormonal
patterns,whileoverfeedinginducescirca-
dian asynchrony, which misaligns hor-
monal and metabolic cycles.
Inadiscussionofnuclearreceptorsas
integrators of circadian rhythms and me-
tabolism (and, hence, as potential phar-
macologic targets), Bart Staels (Lille,
France) reviewed the multiplicity of nu-
clear receptors, particularly those acti-
vated by dietary lipids: peroxisome
proliferator–activated receptor (PPAR),
-, and -; liver X receptor (LXR)- and
-,farnesoidXreceptor(FXR),retinoidX
receptor (RXR), Receptor Tyrosine Ki-
nase-like Orphan Receptors (ROR), and
Rev-erb, of which the latter two are
linked to circadian rhythms. Nuclear re-
ceptors are linked to clock (3,4), with in-
tegration of this system with nuclear
receptors. This suggests transcriptional
control of metabolic pathways by circa-
dianoscillators,withthelight/daytimeef-
fectonthesuprachiasmaticnucleusofthe
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inginitiallyonperipheraltissues,alsoset-
ting in motion circadian pathways
altering metabolic transcription factors.
In the Fenoﬁbrate Intervention and
Event Lowering in Diabetes (FIELD) trial,
theeffectsoffenoﬁbrateonmicrovascular
and peripheral vascular disease were in-
dependent of the degree of glycemic
control and of blood pressure and
medications (5). How, Staels asked,
would activation of PPAR inﬂuence mi-
crovascular disease? He pointed out the
effect of fenoﬁbrate in combination with
the antioxidant CoQ10 on endothelial
function (6), with evidence that the com-
bination also decreases blood pressure,
particularlyloweringnocturnallevels(7),
which would not have been observed in
the data collected in the FIELD study.
Evaluation of physiologic parameters
throughout the diurnal cycle may be im-
portant in better understanding meta-
bolic illness and the effects of treatments.
Rev-erb shows tremendous circa-
dian variation in liver, muscle, adipocyte,
macrophages, and endothelium. Its circa-
dian rhythmicity in liver is maintained in
isolated hepatocytes (8). The related nu-
clear receptor ROR binds to the same
site but with activating effects, while Rev-
erb is inhibitory, although it also inhib-
its its own gene expression, further
affecting the cyclicity, whereas PPAR-
RXR enhances Rev-erb expression.
ROR is bound by hydroxyl-cholesterol,
while Rev-erb is bound by heme, sug-
gesting the complexity of modulators of
circadian rhythmicity. Transcriptional
control of adipogenesis by PPAR is en-
hanced by Rev-erb overexpression.
ROR4 is expressed in visceral and sub-
cutaneous adipose tissues and decreases
adipocyte fatty acid and glucose uptake,
and its overexpression impairs adipocyte
differentiation. In a mouse not expressing
ROR, preadipocyte differentiation is
particularly enhanced when exposed to
PPAR and other activators of adipocyte
differentiation, while introduction of
ROR with a viral vector reverses this ef-
fect. The ROR-deﬁcient mice have in-
creased atherosclerosis, with increased
inﬂammation,althoughtriglyceridelevels
are decreased in ROR-deﬁcient mice
while increased in Rev-erb–deﬁcient
mice, further suggesting an interrelation-
shipofcircadianandmetabolicprocesses.
Bileacidmetabolismhaslongbeenrecog-
nized to have strong circadian rhythmic-
ity, with mice not expressing Rev-erb
having decreased bile acid synthesis as a
result of Rev-erb negatively regulating
cyp7A1, the gene encoding cytochrome
P450 7A1. Furthermore, Rev-erb, the
signalofwhichisincreasedbyPPARand
-, LXR, FXR and ROR, inhibits LXR-
activated pathways in a variety of tissues
in the macrophage affecting the ABCA1
reverse cholesterol transport and TLR4
inﬂammatory processes.
Fred Turek (Chicago, IL) reviewed
sleep and circadian dysregulation and re-
lated disorders, particularly of metabolic
rhythms, referring to an article by Staels
entitled “When the Clock Stops Ticking
Metabolic Syndrome Explodes” (9). Al-
though synchronized in the suprachias-
maticnucleus,clocksgenesarepresentin
all metabolic tissues and control at least
10% of all metabolic processes. There is
an association of shift work with meta-
bolic dysregulation (10), based on a mis-
match of circadian rhythms leading to
metabolic dysregulation. Circadian tim-
ing of food intake contributes to weight
gain, with daytime feeding of mice lead-
ing to weight gain (11), suggesting that
humans,too,byeatingatthewrongtimes
have greater weight gain. Inappropriate
time of feeding is additive to the weight
gain seen in Clock mutant animals.
Ob/ob mice show altered sleep regu-
lation, with increased sleep time but also
greater sleep fragmentation; leptin treat-
mentrapidlynormalizessleeppatternsfar
earlier than the improvement in body
size. Sleep appears to be of great impor-
tance in the development of obesity, dia-
betes, and CVD. There are 4,000 sleep
clinics in the U.S., but Turek would term
what is needed “circadian clinics.” Sleep
deprivation causes metabolic abnormali-
ties; short sleep causes insulin resistance
and, possibly, overweight (12,13) Turek
predicted that coming research will show
relationships of sleep abnormalities to
CVD, cancer, gastrointestinal illness, at-
tention deﬁcit, and depression, and he
showedhisstudyofweeklyreversalofthe
light-dark cycle increasing mortality in a
CVD model (14).
Garet FitzGerald (Philadelphia, PA)
further discussed the molecular clock
from the point of view of its relationship
to CVD (15), reviewing its highly con-
served characteristics from plants to ani-
mals to man and its multiple negative
feedback as well as positive feed-forward
regulators. Experimental models of re-
duced expression of all of the clock genes
do not show eliminated rhythmicity, re-
ﬂecting the high degree of redundancy of
the system (16). There are multiple bio-
logical networks in various tissues, with
the connections between these networks
often involving the clock system, regulat-
ing physiologic processes; the ability to
recover from insulin-induced hypoglyce-
mia, for example, is decreased in animals
not expressing either of the circadian
genes bmal1 or clock (17). There are a
number of oscillating subsets of genes ex-
pressed in vasculature, including those
important in vascular integrity and those
related to carbohydrate and lipid metab-
olism and to adipocyte differentiation
(which make use of the clock systems),
and speciﬁc coactivaors and corepressors
suchassirt1affectclocksystems(18).The
relationship of metabolism to the clock
system is suggested by the circadian pat-
ternsofplasmametabolites(19).Micenot
expressing the clock system component
gene Bmal1 have accelerated atheroscle-
rosis in a high fat–induced atherogenesis
model, and adipocyte tissue–speciﬁc
Bmal1 suppression leads to obesity with
standard as well as with high-fat diets,
with increased food intake during the
light period of normally reduced nutrient
ingestion and with muscle insulin resis-
tancebutincreasedadipocyteglucoseup-
take. Circadian rhythms in blood
pressure are related to the diurnal varia-
tion in myocardial infarction and stroke
frequency (20), although this does not
prove whether the epidemiologic ﬁnding
is related to clock or is a time-dependent
effect of environmental stressors. When
this question was addressed in a vascular
injury model, thrombus formation
showed diurnal variation, which was
abolished by endothelium-speciﬁc inacti-
vating clock mutations (21). Bmal1 and
clockarecriticaltothemaintenanceofcir-
cadian rhythms in blood pressure (22).
FitzGeraldconcludedthatthethreemajor
clock genes, bmal1, clock, and cry likely
have distinct roles in maintaining circa-
dianvariationinbloodpressureandpulse
and possibly regulating catecholamine
levels, with catecholamine o-methyl
transferase expression under tissue-
speciﬁc circadian control. Bmal1 modu-
lates the stress response, with the
hypertensive response of mice to immo-
bilization abolished in animals not ex-
pressing bmal1 but the steroid response
conserved suggesting other mediators.
The system is robust and highly con-
served and regulated, with core elements
of the clock inﬂuencing thrombogenesis,
bloodpressure,andlipidandglucoseme-
tabolism,andhavingimpactonanumber
of regulatory systems relevant to cardio-
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speculate that communications must oc-
cur between peripheral clocks and those
in the central nervous system.
Adipocytes and insulin resistance
A number of different views of the adipo-
cyte and its relationship to insulin resis-
tance were presented at the Congress.
Sonia Caprio (New Haven, CT) reviewed
the role of ectopic fat and the relation-
ships between adipocyte size and adipo-
genic potential of subcutaneous tissue,
inﬂammation, and insulin resistance in
obese adolescents. There is a great deal of
heterogeneity in insulin resistance among
obeseadolescents,withstudiesofinsulin-
resistant obese, insulin-sensitive obese,
andleanadolescentsshowingmuscleand
visceral fat composition to predict the de-
gree of insulin resistance (23,24). Fat
storage may take place in subcutaneous,
pericardial, perivascular, or visceral adi-
pose tissue in or insulin-sensitive tissues
such as liver, skeletal muscle, and pan-
creas. Focusing on ectopic fat in liver and
muscle to identify factors that cause some
but not other obese children to develop
abnormal glucose metabolism, Caprio
asked whether the degree or the distribu-
tion of obesity is of greatest importance.
Limited or inefﬁcient fat storage in the
subcutaneous depot might be related to
liver, muscle, and visceral fat accumula-
tion. In a study of 118 obese adolescents,
stratiﬁed by visceral fat, there was an in-
verse relationship between visceral and
subcutaneous fat, while visceral fat corre-
lated with hepatic fat, with the degree of
insulin resistance when fasting insulin–
basedmeasureswereused,aswellaswith
prevalence of metabolic syndrome (25).
Liver fat was associated with the likeli-
hoods of impaired glucose tolerance, im-
paired fasting glucose, and type 2
diabetes. Subcutaneous fat biopsy was
performed in 15 study participants with
low visceral/high subcutaneous fat and in
18 with high visceral/low subcutaneous
fat, revealing an expanded population of
small adipose cells and impaired adipose
cell differentiation in the latter group in
association with increased visceral and
hepatic fat and with insulin resistance;
subcutaneous fat characteristics did not
correlatewithmusclefat.PPAR2expres-
sion appeared to reﬂect the abnormality
ofimpairedadipocytedifferentiation,and
atrendtogreaterdegreesofadiposetissue
macrophage inﬁltration was seen in the
biopsy specimens from children with in-
sulin resistance.
Sam Cushman (Bethesda, MD) fur-
ther discussed fat cell size distribution
studies. Adipocytes, he said, consist of a
“huge lipid droplet” with cellular ele-
ments contained in an outer rim of the
cell. Adipocytes have secretory as well as
storagefunctions,withadipocyte-speciﬁc
deletion of the glucose transporter
(GLUT)4 causing muscle and whole-
body insulin resistance, presumably re-
lated to secreted factors or to ectopic fat
deposition.Inanalysisoffatcellsizeof11
insulin-resistant and 15 insulin-sensitive
individuals, both groups had large but
similar numbers of small adipocytes and
(contrarytothehypothesis)thesizeofthe
large adipocytes was roughly similar be-
tween the groups.
Adipocytes maturation proceeds,
with undetermined controlling factors,
from stem cells to preadipocytes, with
subsequent adipocyte formation con-
trolled by activation of the nuclear recep-
tor PPAR. The methodology used does
not give speciﬁc information about very
small cells but allows quantitation of cells
varying from 20 to 200 microns in size.
Measurement of mean cell size (to assess
hypertrophy) and total cell number (to
assess hyperplasia) allows ascertainment
of recruitment, growth/shrinkage, ﬂuctu-
ation,anddeathofadipocytes.Onahigh-
fatdietwithprogressiveweightgain,large
adipocyte numbers decreased but size in-
creased, suggesting more rapid growth
but with greater susceptibility to cell
death; all the fat depots studied had sim-
ilar behavior. After the high-fat diet was
stopped, the number of small cells de-
creased, suggesting death of precursor
cells, with reduction in size of the large
adipocytes.Overtimetherewerecyclesof
cell growth. With administration of ros-
iglitazone there was rapid recruitment of
adipocytes with increase in cell number
over the initial 10 days and a subsequent
shift from smaller to larger cells, although
Cushman pointed out that thiazo-
lidinediones may not actually stimulate
differentiation of stem cells, which would
explain why the initial “burst” is followed
by increase in adipocyte size rather than
number. He hypothesized that adipogen-
esis is triggered when available adipose
cells cannot absorb the energy ﬂux.
Tracy McLaughlin (Stanford, CA)
discussed the relationship of insulin re-
sistance to obesity. The correlation co-
efﬁcient of steady-state plasma glucose
(SSPG) with BMI in a large study was
0.58, suggesting “a large amount of vari-
ability at any given BMI.” In the most in-
sulin-resistanttertile,asBMIincreasesthe
prevalence of insulin resistance increases,
but even with severe obesity some indi-
viduals are in the mid-tertile of insulin
resistance.“Thisrelationshipisverylikely
to explain the clinical morbidities associ-
ated with obesity,” she said, because in
every BMI group, those in the more insu-
lin-resistant tertile have higher blood
pressure,triglyceride,andfastingand2-h
glucose. Individuals with insulin resis-
tance who maintain weight loss show sta-
bility or even further improvement in
SSPG, although those who are insulin
sensitive initially do not have further im-
provement (26). Lipids, inﬂammatory
markers, and asymmetric dimethylargin-
ine improved in the insulin resistant
group, while those who were insulin sen-
sitive at baseline did not show change in
these parameters with weight loss (27).
McLaughlin posed a number of questions
that have not been fully answered regard-
ing the interrelationships of obesity
and insulin resistance. Why do thiazo-
lidinediones, acting at adipocyte nuclear
receptors, improve insulin action in skel-
etal muscle? Does visceral fat promote
insulin resistance or is impaired subcuta-
neous fat storage the actual abnormality,
withthesubcutaneousadipocytehavinga
protective role? Are individuals with
greater capacity for adipocyte differen-
tiation and proliferation inherently less
likely to develop ectopic fat and, hence,
insulin resistance? McLaughlin pointed
out the association of insulin resistance
with intramyocellular fat (28) in support
of this notion. She reviewed the conﬂict-
ing data regarding the relationship of adi-
pocytesizewithinsulinsensitivity,noting
that there are increased proportions of
small adipocytes in insulin resistance but
that thiazolidinediones further increase
thesmall adipocyte number, although it
maybethatthesesmallcellswouldsub-
sequently increase in size and so pro-
mote greater insulin sensitivity. The
peak adipocyte diameter increases with
weight for individuals with BMI 25–
29.9kg/m
2,butfromBMIlevelsof30to
50 kg/m
2 there is no further increase
in adipocyte peak diameter. Does obe-
sity involve stimulation of differentia-
tion of new cells?
Phillip Scherer (Dallas, TX) discussed
relationships between adipose tissue dys-
functionandinsulinresistance.Heasked:
what are the major issues encountered
during fat expansion leading (in dysfunc-
tional adipose tissue) to inﬂammation?
He showed histologic evidence of in-
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tissue of obese animals, which can be
showninmeasurementofavarietyofcol-
lagen molecules, with PPAR agonist
treatmentdownregulatingthisproﬁbrotic
signal. Scherer compared lean and ob/ob
mice and ob/ob mice not expressing colla-
genVI;fatcellsizefurtherincreasedinthe
latter group, but glucose tolerance im-
proved, suggesting that adipose tissue ﬁ-
brosis prevents further expansion,
causingnecrosisandleadingtoinsulinre-
sistance(29).Anotherissueisadiposetis-
sue hypoxia. Expanding fat has similarity
to expanding malignant tissue in its po-
tential for an inadequate vascular supply.
The vascular density of fat in the ob/ob
mouseisdecreased,withattenuatedpost-
prandial increase in fat pad blood ﬂow.
On a high-fat diet, then, fat cells may rap-
idly expand, causing local hypoxia and
triggering signals such as hypoxia-
inducible factor 1, which stimulates ﬁ-
brosis and oxidative processes, leading to
necrosisandthentolocalfollowedbysys-
temic inﬂammation. The presence in adi-
pose tissue of macrophages and in
circulation of inﬂammatory markers may
then be late occurrences. PPAR agonists
are antiﬁbrotic, stimulate angiogenesis,
and inhibit macrophages, preventing this
process.
Adiponectin is unique among adipo-
cyte cytokines in that its plasma levels
correlate inversely with fat mass. It corre-
lates with greater insulin sensitivity, is
suppressed by inﬂammatory processes,
and is increased by PPAR agonists. It is a
complicated molecule circulating in tri-
mer, hexamer, and multimer forms. Fe-
males have higher total and high-
molecular weight adiponectin levels due
to levels of the high–molecular weight
form, which correlates better than total
levels with insulin sensitivity (30). It cir-
culates at high levels but turns over rap-
idly, and its role has not yet been
determined (31). Another relevant con-
ceptisendoplasmicreticulum(ER)stress,
which is associated with obesity and de-
creases in obese individuals after weight
loss (32). ER stress and hypoxia appear to
suppress adiponectin secretion so that it
may be seen as an integrated marker of
adipose tissue health, with anti-
inﬂammatory, antisteatotic, insulin-
sensitizing (particularly in liver [33]),
cardioprotective, antiﬁbrotic, and anti-
apoptotic effect, although a unifying
mechanism has not been described.
Scherer noted the possibility that, as with
PPAR agonists, its angiogenic effect
could promote tumor growth. He sug-
gested that adiponectin appears to be in-
volved in the “metabolic ﬂexibility”
sustaining insulin sensitivity. “When you
hear ‘dysfunctional fat,’” he concluded,
“think hypoxia, ﬁbrosis, and also the
stress response, the unfolded protein re-
sponse.” These in turn cause systemic
inﬂammation.
Ulf Smith (Gothenburg, Sweden) dis-
cussed aspects of impaired differentiation
of human preadipocytes in abdominal
obesity and insulin resistance. He sug-
gested that “waist circumference is a
better marker than BMI” of insulin re-
sistance, noting that 25–30% of obese
individuals are not insulin resistant while
25% of nonobese individuals are insulin
resistant. Irrespective of BMI, he said, en-
larged fat cells are associated with insulin
resistance (using a different methodology
from that described by Cushman and
McLaughlin). He then termed insulin re-
sistance obesity “hypertrophic obesity,”
which he contrasted with hypercellular
obesity not related to insulin resistance.
Obese mice overexpressing adiponectin,
for example, have normal insulin sensi-
tivity despite massive obesity, further
supporting this notion. He noted that
subcutaneous fat comprises most adipose
tissue and suggested that visceral fat, like
epicardial and liver fat, be considered “an
ectopic depot” (34).
Enlargedadipocytes,hesaid,recruitin-
ﬂammatory cells, including T-lymphocytes
expressingCD3(involvedinacquiredim-
mune system activation) and CD8 (in-
volved in macrophage recruitment), mast
cells (35), and plasma cells. This contrib-
utes to insulin resistance by producing a
variety of proinﬂammatory cytokines and
by showing increased nuclear factor-B
and c-Jun kinase pathway activity, lead-
ing macrophages to assume a proinﬂam-
matory phenotype (36). Tumor necrosis
factor- is produced by adipocytes in an
inactive form, requiring local inﬂamma-
tory cells for activation, and acts to pre-
vent differentiation of preadipocytes into
fully differentiated adipocytes, which fur-
ther produce inﬂammatory cells and dis-
play a macrophage-like phenotype rather
than accumulating lipids, reducing re-
cruitment of new adipocytes (37).
Smithasked,“Whydon’tthecellsdif-
ferentiate?” The Wnt signaling pathway,
ﬁrst described in Drosophila, is involved
in growth and development, keeping
stem cells in an undifferentiated state,
withabnormalitiesinthispathwayrelated
to oncogenesis. Wnt ligands bind to
membrane receptors including TCF7L2,
polymorphisms of which are the most
well recognized risk genes for type 2 dia-
betes.Wntactivationincreasesintracellu-
lar concentrations of -catenin, which in
turn induces a variety of genes. When
Wnt is not present during differentiation,
-catenin is degraded. Smith suggested
that tumor necrosis factor- acts via Wnt
activation. Wnt signaling leads in bone
marrow to formation of osteoblasts rather
than adipocytes from precursors, and it
appears that a mechanism of thiazo-
lidinediones reducing bone mineral den-
sity involves PPAR induction of an
inhibitor of Wnt, favoring differentiation
into preadipocytes, while cytokines in-
crease Wnt signaling. WISP-2, a marker
of Wnt signaling, is associated with obe-
sity, intra-abominal fat and high waist-to-
hip ratio, and risk factors for type 2
diabetes. WISP-2 is elevated in newly di-
agnosed type 2 diabetes.
Michael Jensen (Rochester, MN) dis-
cussed the role of dysregulated adipose
tissuelipolysisinthemetaboliccomplica-
tions of obesity, pointing out that lower-
body obesity is associated with normal
freefattyacid(FFA)andupper-body(and
visceral) obesity with high FFA. The por-
tal fat hypothesis is that lipolysis by vis-
ceral fat cells is increased, increasing FFA
ﬂux to the liver (38). Jensen pointed out
that insulin resistance is associated with
high FFA and that experimental ap-
proaches increasing FFA reduce muscle
insulin sensitivity, increased insulin se-
cretion, and increase hepatic glucose out-
put,suggestingFFAtobeacentralplayer.
Adipocyte FFA release is tightly linked to
metabolism, which is increased in the
fasting state or with exercise, when lipol-
ysis may increase ﬁvefold, whereas after
feeding—when FFA production is not re-
quired—insulin rapidly inhibits lipolysis
by 90%; the range from lowest to high-
est levels of FFA release is 50-fold. FFA
release is greater with upper-body obe-
sity, which is associated with less sup-
pression during a hyperinsulinemic
clamp (39) or in the postprandial state
(40). Jensen pointed to evidence that up-
per-body subcutaneous fat FFA release is
less well inhibited than that from the
splanchnicbedorlegpostprandially(41),
suggesting that visceral fat is not the
source of increased circulating FFA and
likely contributes to FFA delivered to the
liver rather than that entering the sys-
temiccirculation(42).Upper-bodyrather
than visceral obesity, then, may be asso-
ciated with elevation in circulating FFA,
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pancreas is perfused by the systemic cir-
culation) and, perhaps by its effect on the
vasculature or on intramyocellular fat, to
insulin resistance.
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